Trials / Unknown
UnknownNCT00702247
Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)
Allogeneic Stem Cell Transplantation for Multiple Myeloma: a Two Step Approach to Reduce Toxicity Involving High-Dose Melphalan and Autologous Stem Cell Transplant Followed by PBSC Allografting After Low-Dose TBI
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Azienda Ospedaliera San Giovanni Battista · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate toxicity profile and efficacy of a tandem autologous-nonmyeloablative transplant approach in newly diagnose myeloma patients younger than 65 years
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Hematopoietic Stem Cell Transplantation |
Timeline
- Start date
- 1999-07-01
- First posted
- 2008-06-20
- Last updated
- 2008-06-20
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT00702247. Inclusion in this directory is not an endorsement.